Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BBP-631 gene therapy in congenital adrenal hyperplasia
NCT04783181Phase 2Active, not recruiting
- Sponsor
- Adrenas Therapeutics, Inc.
- Start
- Jul 2021
- Primary completion
- Feb 2029
- Modality
- Gene Editing, Gene Silencing, AAV Vectors
- Countries
- 1
01
Overview
A Phase 2 trial of BBP-631 in congenital adrenal hyperplasia (CAH), sponsored by Adrenas Therapeutics, Inc.. Started Jul 2021; status: active, not recruiting.
02
Drugs
BBP-631
03
Conditions
congenital adrenal hyperplasia (CAH)
Beyond the preview
Go deeper on NCT04783181.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04783181.